Mirum Pharmaceuticals
Pharmaceuticals, 950 Tower Ln Ste 1050, Foster City, California, 94404, United States, 201-500 Employees
Phone Number: 65********
Who is MIRUM PHARMACEUTICALS
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LI...
Read More
-
Headquarters: 950 Tower Ln Ste 1050, Foster City, California, 94404, United States
-
Date Founded: 2018
-
Employees: 201-500
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 561110 |
Show More
Does something look wrong? Fix it. | View contact records from MIRUM PHARMACEUTICALS
Mirum Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Mirum Pharmaceuticals
Answer: Mirum Pharmaceuticals's headquarters are located at 950 Tower Ln Ste 1050, Foster City, California, 94404, United States
Answer: Mirum Pharmaceuticals's phone number is 65********
Answer: Mirum Pharmaceuticals's official website is https://mirumpharma.com
Answer: Mirum Pharmaceuticals's revenue is $10 Million to $25 Million
Answer: Mirum Pharmaceuticals's SIC: 2834
Answer: Mirum Pharmaceuticals's NAICS: 561110
Answer: Mirum Pharmaceuticals has 201-500 employees
Answer: Mirum Pharmaceuticals is in Pharmaceuticals
Answer: Mirum Pharmaceuticals contact info: Phone number: 65******** Website: https://mirumpharma.com
Answer: Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI (maralixibat) oral solution, Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in Canada. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older. Cholbam is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. Chenodal has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX). Mirums late-stage pipeline includes three investigational treatments for debilitating liver diseases. The LIVMARLI development program includes the Phase 2b EMBARK study for biliary atresia. Mirums second investigational IBAT inhibitor is volixibat, which is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, Chenodal, is being evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month